Fate Therapeutics (FATE)
(Delayed Data from NSDQ)
$3.80 USD
-0.07 (-1.81%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $3.80 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth A Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$3.80 USD
-0.07 (-1.81%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $3.80 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth A Momentum F VGM
Zacks News
Myovant Sciences (MYOV) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Myovant Sciences (MYOV) delivered earnings and revenue surprises of 4.08% and 13.94%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Should You Invest in the SPDR S&P Biotech ETF (XBI)?
by Zacks Equity Research
Sector ETF report for XBI
Fate Therapeutics (FATE) Down 17% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Fate Therapeutics (FATE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
FATE's Q2 Loss Narrower Than Expected, Pipeline in Focus
by Zacks Equity Research
FATE reports a narrower loss and higher collaboration revenues in the second quarter.
Fate Therapeutics (FATE) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Fate Therapeutics (FATE) delivered earnings and revenue surprises of 8.14% and 38.21%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for XBI
Acadia (ACAD) Files an NDA for Its Rett Syndrome Candidate
by Zacks Equity Research
Acadia (ACAD) submits a new drug application to the FDA for trofinetide to treat Rett syndrome in patients aged two and older.
Ultragenyx (RARE) Provides Update From Angelman Syndrome Study
by Zacks Equity Research
Ultragenyx (RARE) and GeneTx Biotherapeutics provide an update and positive interim data from the phase I/II study on GTX-102 for treating patients with Angelman syndrome.
Amryt (AMYT) Mycapssa Gets Orphan Drug Tag for Carcinoid Syndrome
by Zacks Equity Research
The FDA bestows an Orphan Drug designation to Amryt's (AMYT) Mycapssa for the treatment of carcinoid syndrome. Stock up in pre-market trading.
Perrigo (PRGO) Unit Files for OTC Birth Control Pill With FDA
by Zacks Equity Research
The FDA's potential approval of Perrigo (PRGO) unit, HRA Pharma's OTC birth control pills can make the drug the first of its kind to be made available without prescription in the United States.
Why Is Kodiak Sciences Inc. (KOD) Up 88.3% Since Last Earnings Report?
by Zacks Equity Research
Kodiak Sciences Inc. (KOD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Is Fate Therapeutics (FATE) Down 14.1% Since Last Earnings Report?
by Zacks Equity Research
Fate Therapeutics (FATE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
FATE's Loss Narrower Than Expected in Q1, Pipeline in Focus
by Zacks Equity Research
FATE reports a narrower loss and higher collaboration revenues in the first quarter.
Fate Therapeutics (FATE) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Fate Therapeutics (FATE) delivered earnings and revenue surprises of 12.82% and 85.93%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Fate Therapeutics (FATE) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Fate Therapeutics (FATE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Fate Therapeutics (FATE) Up 21.9% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Fate Therapeutics (FATE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
FATE's Loss Wider Than Expected in Q4, Pipeline in Focus
by Zacks Equity Research
FATE reports a wider loss on increased R&D expenses in the fourth quarter.
Fate Therapeutics (FATE) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Fate Therapeutics (FATE) delivered earnings and revenue surprises of -5.88% and 30.84%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
FATE's Q3 Loss Narrower Than Expected, Pipeline in Focus
by Zacks Equity Research
FATE reports a year-over-year wider loss on increased R&D expenses in the third quarter.
Fate Therapeutics (FATE) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Fate Therapeutics (FATE) delivered earnings and revenue surprises of 1.72% and 64.34%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Fate Therapeutics (FATE) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Fate Therapeutics (FATE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Is Fate Therapeutics (FATE) Down 21% Since Last Earnings Report?
by Zacks Equity Research
Fate Therapeutics (FATE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
FATE Reports Wider-Than-Expected Q2 Loss, Beats on Revenues
by Zacks Equity Research
FATE reports a wider loss on increased R&D expenses in the second quarter.
Fate Therapeutics (FATE) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Fate Therapeutics (FATE) delivered earnings and revenue surprises of -11.54% and 89.70%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Fate Therapeutics (FATE) Q2 Earnings Expected to Decline
by Zacks Equity Research
Fate Therapeutics (FATE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.